NDLI: Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus

Content Provider	PubMed Central
Author	Yeaman, Michael R. Filler, Scott G. Schmidt, Clint S. Ibrahim, Ashraf S. Edwards, John E. Hennessey, John P.
Copyright Year	2014
Abstract	Recent perspectives forecast a new paradigm for future “third generation” vaccines based on commonalities found in diverse pathogens or convergent immune defenses to such pathogens. For Staphylococcus aureus, recurring infections and a limited success of vaccines containing S. aureus antigens imply that native antigens induce immune responses insufficient for optimal efficacy. These perspectives exemplify the need to apply novel vaccine strategies to high-priority pathogens. One such approach can be termed convergent immunity, where antigens from non-target organisms that contain epitope homologs found in the target organism are applied in vaccines. This approach aims to evoke atypical immune defenses via synergistic processes that (1) afford protective efficacy; (2) target an epitope from one organism that contributes to protective immunity against another; (3) cross-protect against multiple pathogens occupying a common anatomic or immunological niche; and/or (4) overcome immune subversion or avoidance strategies of target pathogens. Thus, convergent immunity has a potential to promote protective efficacy not usually elicited by native antigens from a target pathogen. Variations of this concept have been mainstays in the history of viral and bacterial vaccine development. A more far-reaching example is the pre-clinical evidence that specific fungal antigens can induce cross-kingdom protection against bacterial pathogens. This trans-kingdom protection has been demonstrated in pre-clinical studies of the recombinant Candida albicans agglutinin-like sequence 3 protein (rAls3) where it was shown that a vaccine containing rAls3 provides homologous protection against C. albicans, heterologous protection against several other Candida species, and convergent protection against several strains of S. aureus. Convergent immunity reflects an intriguing new approach to designing and developing vaccine antigens and is considered here in the context of vaccines to target S. aureus.
Related Links	http://dx.doi.org/10.3389/fimmu.2014.00463
Starting Page	463
File Format	PDF
ISSN	16643224
e-ISSN	16643224
Journal	Frontiers in Immunology
Volume Number	5
Language	English
Publisher	Frontiers Media S.A.
Publisher Date	2014-09-01
Access Restriction	Open
Rights Holder	Frontiers Media S.A.
Subject Keyword	Research in Higher Education
Content Type	Text
Resource Type	Article
Subject	Immunology and Allergy Immunology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus

AN EXPERIMENTAL STUDY OF OPSONIC IMMUNITY TO STAPHYLOCOCCUS AUREUS

Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity

FURTHER EXPERIENCES WITH NON-SPECIFIC LOCAL CUTANEOUS IMMUNITY TO STAPHYLOCOCCUS AUREUS

The secondary immune response to Staphylococcus aureus vaccines in efferent popliteal lymph of sheep.

Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus

Prevention of Staphylococcus aureus Infections by Glycoprotein Vaccines Synthesized in Escherichia coli

Abnormal humoral immune response to Staphylococcus aureus in patients with Staphylococcus aureus hyper IgE syndrome.

Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against S. aureus and Staphylococcus epidermidis

Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus

Similar Documents

Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus

AN EXPERIMENTAL STUDY OF OPSONIC IMMUNITY TO STAPHYLOCOCCUS AUREUS

Metal ion acquisition in Staphylococcus aureus: overcoming nutritional immunity

FURTHER EXPERIENCES WITH NON-SPECIFIC LOCAL CUTANEOUS IMMUNITY TO STAPHYLOCOCCUS AUREUS

The secondary immune response to Staphylococcus aureus vaccines in efferent popliteal lymph of sheep.

Role and plasticity of Th1 and Th17 responses in immunity to Staphylococcus aureus

Prevention of Staphylococcus aureus Infections by Glycoprotein Vaccines Synthesized in Escherichia coli

Abnormal humoral immune response to Staphylococcus aureus in patients with Staphylococcus aureus hyper IgE syndrome.

Staphylococcus aureus Manganese Transport Protein C Is a Highly Conserved Cell Surface Protein That Elicits Protective Immunity Against S. aureus and Staphylococcus epidermidis

Applying Convergent Immunity to Innovative Vaccines Targeting Staphylococcus aureus